Abstract:Background and objectives: In the United States, intravenous vitamin D analogs are the first-line therapy for management of secondary hyperparathyroidism in hemodialysis patients. Outside the United States, oral calcitriol (1,25-dihydroxyvitamin D3) is routinely used. We examined standard laboratory parameters of patients on in-center hemodialysis receiving intravenous vitamin D who switched to oral calcitriol. Design, setting, participants, & measurements: We conducted a retrospective cohort study of adult patients treated within Fresenius Kidney Care clinics. During a 6-month period (December 2013 to May 2014), we identified patients on an intravenous vitamin D analog (doxercalciferol or paricalcitol) who switched to oral calcitriol and matched them to patients receiving an intravenous vitamin D analog. Mean serum calcium, phosphate, and intact parathyroid hormone (iPTH) concentrations were examined for up to 12 months of follow-up. We used Poisson and Cox proportional hazards regression models to examine hospitalization and survival rates. The primary analysis was conducted as intention-to-treat; secondary analyses included an as-treated evaluation. Results: A total of 2280 patients who switched to oral calcitriol were matched to 2280 patients receiving intravenous vitamin D. Compared with patients on intravenous vitamin D, mean calcium and phosphate levels in the oral calcitriol group were lower after the change to oral calcitriol. In contrast, iPTH levels were higher in the oral calcitriol group. At 12 months, the percentage of patients with composite laboratories in target range (calcium <10 mg/dl, phosphate 3.0-5.5 mg/dl, and iPTH 150-600 pg/ml) were comparable between groups (45% versus 45%; P=0.96). Hospital admissions, length of hospital stay, and survival were comparable between groups. An as-treated analysis and excluding those receiving cinacalcet did not reveal significant between-group differences. Conclusions: Among patients receiving in-center hemodialysis who were switched to oral calcitriol versus those on an intravenous vitamin D analog, the aggregate of all mineral and bone laboratory parameters in range was largely similar between groups.

Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis

An Investigator‐masked Comparison of the Efficacy and Safety of Twice Daily Applications of Calcitriol 3 Μg/g Ointment Vs. Calcipotriol 50 Μg/g Ointment in Subjects with Mild to Moderate Chronic Plaque‐type Psoriasis

Topical Treatment of Calcipotriol Decreases Expression of ICAM-3 Positive Infiltrating Leukocytes in Psoriatic Skin

Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Calcipotriol Scalp Solution In The Treatment Of Scalp Psoriasis: A Randomized, Controlled Trial Investigating Efficacy And Safety In A Chinese Population

Comparison of Safety and Efficacy Between Calcipotriol Plus Betamethasone Dipropionate Gel and Calcipotriol Scalp Solution As Long-Term Treatment for Scalp Psoriasis in Chinese Patients: a National, Multicentre, Prospective, Randomized, Active-Controlled Phase 4 Trial

Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long‐term therapy for mild‐to‐moderate plaque psoriasis

Efficacy and safety of vitamin D supplementation on psoriasis: A systematic review and meta-analysis

Calcipotriol Betamethasone Ointment in the Treatment of Psoriasis Vulgaris: a Randomized, Double-Blind, Active-Controlled, Parallel Group Study.

The effect of long-term treatment with tacalcitol on the psoriatic epidermis. A flow cytometric analysis

Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis

Safety and Efficacy of Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in the Treatment of Extensive Scalp Psoriasis in Adolescents Ages 12 to 17 Years

Calcitri01 ointment versus calcipotriol ointment in the treatment of psoriasis: a single-blind, randomized, multicenter trial

Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids

Effect of daivobet® on the quality of life in chinese patients with stable psoriasis vulgaris: A multicenter, randomized, double-blind, positive controlled and parallel group study

THE EFFECT OF PARICALCITOL AND CALCITRIOL WITH OR WITHOUT CALCIMIMETICS ON PULSE WAVE VELOCITY AND SERUM LEVELS FOR PARATHYROID HORMONE, CALCIUM AND PHOSPHORUS IN MAINTENANCE HEMODIALYSIS PATIENTS

Controlled Trial of the Effects of 1,25-Dihydroxycholecalciferol in Patients Treated with Regular Dialysis

Expression of integrin subunits and CD44 isoforms in psoriatic skin and effects of topical calcitriol application

Oral Calcitriol for Reduction of Proteinuria in Patients with IgA Nephropathy: a Randomized Controlled Trial.

Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial—POSCAL Study

Efficacy, Safety, and Cost-Effectiveness of All-Trans Retinoic Acid/clobetasol Propionate Compound Ointment in the Treatment of Mild to Moderate Psoriasis Vulgaris: A Randomized, Single-Blind, Multicenter Clinical Trial.

Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study